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  Diabetes mellitus is a common metabolic disorder affect-
ing millions of people worldwide. The prevalence of this 
chronic, endocrine condition continues to grow, from a 
world-wide prevalence of 221 million in 2010 to a projected 
300 million in 2030 [1, 2]. The majority (~90%) of patients 
suffering from diabetes mellitus have type 2 while about 
10% have type 1. Type 1 diabetes is caused by immunologi-
cal destruction of pancreatic beta cells leading to absolute 
insulin deficiency. On the other hand, type 2 diabetes is as-
sociated with deficient insulin secretion and/or insulin resis-
tance. The etiology of diabetes mellitus is multifactorial in-
volving both genetic and environmental factors.  
  The multifactorial nature of the disease makes manage-
ment of the diabetes difficult and in many cases multifac-
eted. While insulin might be nearly sufficient in the treat-
ment of type 1 diabetes, a more diverse approach is needed 
for the amelioration of the signs and symptoms of patients 
suffering from type 2 diabetes. 
  Several non-pharmacological approaches have been em-
ployed to manage patients with type 2 diabetes. Physical 
exercise with or without weight loss have been shown to 
improve glycemic control [3, 4]. Physical exercise such as 
progressive resistance training has been reported to signifi-
cantly lower blood glucose level in patients suffering from 
type 2 diabetes [4]. In addition, a low calorie diet with a low 
glycemic index is also useful in lowering glycemic level [5]. 
  Since the etiology of diabetes mellitus is multifactorial, 
the pharmacological approach would warrant a multidirec-
tional treatment as well. Several groups of pharmaceutical 
agents are used to target different phases of the metabolism 
of the pancreatic beta cell in order to generate an optimal 
secretion of insulin. 
  Oral hypoglycemic agents including, sulfonylureas, 
which induces the release of insulin after binding with the 
sulfonylurea receptors on pancreatic beta cell are widely 
used for the treatment of type 2 diabetes. The biguanides, a 
drug that does not necessarily induce insulin secretion but 
reduce hepatic glucose output [6] is also an ‘old hand’ in the 
pharmacotherapy of type 2 diabetes. Biguanides also in-
crease peripheral uptake of glucose [7]. All of these actions  
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of biguanides help to reduce blood glucose level in diabetic 
patients.  
  In spite of the success achieved with the use of the older 
generation of oral anti-diabetic agents, the severity and 
prevalence of diabetes complications continue to be high, 
hence the need for newer medications in the fight against the 
signs and symptoms of diabetes mellitus. 
  Research into ways of treating diabetes mellitus has led 
to the discovery of thiazolidinediones. These drugs bind to 
nuclear molecules, called peroxisome proliferator-activated 
receptor (PPAR). Stimulation of PPAR will in turn activate 
genes responsible for insulin release. The medicinal 
chemistry of this class of anti-diabetic drug is a subject of 
this Special Issue. The discovery of dual PPAR agonists is 
particularly interesting because it is capable of controlling 
diabetes mellitus and at the same time preventing the 
complications associated with it.  
  In addition, incretins such as GLP-1 and bioactive agents 
that block DPP-4 (vidagliptin) are relatively new, but 
promising tools in the arsenal of drugs used in the treatment 
of diabetes. DPP-4 is the enzyme that degrades GLP-1.The 
medicinal chemistry of this group of drug is addressed in this 
Issue. 
  Meglitinide analogues target pancreatic beta cell 
receptors to induce insulin release by attaching to the 
sulfonylurea receptor subunit and closing the K+ ATP 
channel concomitantly [8]. 
  Alpha-glucosidase inhibitor (e.g. acarbose, miglitol) is 
yet another drug used in the treatment of diabetes mellitus. 
Alpha-glucosidase inhibitors delay the digestion of complex 
carbohydrates resulting in a decrease in blood glucose [9]. 
  Amylin, which is released with insulin from pancreatic 
beta cell, is used after structural modification, as adjunct 
therapy in the treatment of type 1 diabetes. It is particularly 
favored in pediatric patients. The functions and medicinal 
chemistry of amylin is discussed in this Special Issue. 
  Insulin, given subcutaneously, comes in different prepa-
rations including short-, intermediate- and long-acting. Other 
forms of insulin preparation including nasal insulin spray 
have also been experimented. Further development of this 
type of insulin is under intense focus [10]. Other insulin 
preparation include thyroxyl-insulin, an insulin linked to 
thyroxin, binds strongly to plasma proteins via its thyroxyl Medicinal Chemistry of Novel Anti-Diabetic Drugs   The Open Medicinal Chemistry Journal, 2011, 5    69 
molecule, resulting in a prolonged plasma half-life and little 
chance of diffusing through the vascular endothelium [5]. 
All of these result in a longer insulin action. 
  Studies examining the role of herbs in the treatment of 
diabetes have been gaining momentum in the last few 
decades and many herbs have been characterized as having 
hypoglycemic action [11]. One medicinal plant that has been 
getting a lot of attention is Mormodica charantia. The fruit 
juice of this plant has been shown to have hypoglycemic 
effect [12-14]. The medicinal chemistry of this plant is 
discussed in detail in this Special Issue. 
FUTURE OUTLOOK 
  Improved knowledge of the chemical nature of bioactive 
agents, whether natural or synthetic will contribute to further 
discoveries of many more therapeutic agents for the treat-
ment of diabetes in the near future. These developments will 
reduce the severity of the signs and symptoms of diabetes 
mellitus. 
  I would like to thank all contributors to this Special Issue. 
We hope that this Special Issue on the medicinal chemistry 
of novel anti-diabetic drugs will help in the development of 
more potent and optimal anti diabetic drugs in the not too 
distant future.  
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